Workflow
DHA藻油
icon
Search documents
恒诺世佳董事长的教育初心
Sou Hu Cai Jing· 2025-08-27 08:51
在青岛恒诺世佳健康产业园,每天清晨都会响起两句口号:"为健康护航,为生命负责""让老百姓花小 钱,享好产品"。这两句被员工刻在心里的话,藏着创始人王桂森与母亲的一段往事,也藏着一个品牌 从青岛初创到深耕健康领域的成长密码。从虾青素实验室到加盟门店,从健康科普课堂到久久峰会的交 流现场,恒诺世佳用四年时间证明:大健康产业的终极竞争力,从来不只是产品,更是对 "让老百姓花 很小的钱,用上世界一流的产品" 的执着。 初心:一瓶虾青素里的孝心与敬畏 2017 年深秋,王桂森在母亲的病床前攥紧了拳头。类风湿关节炎折磨了母亲七年,他带着老人跑遍全 国医院,却终究没能留住她。这成了王桂森一辈子的遗憾,也成了他后来创业的全部动力。 在后来的一场健康论坛。当专家提到 "雨生红球藻虾青素的抗氧化力是维生素 E 的 1000 倍" 时,王桂森 眼前突然一亮—— 这个被称为 "自然界抗氧化之王" 的物质,不正是他要找的答案吗? 如今,同类虾青素产品市场动辄上千,恒诺世佳却把价格降低,"让老百姓吃虾青素比吃馒头还便宜"正 是王桂森的孝心与大爱的完美诠释。而这背后,正是企业 "做中国老百姓的健康管家" 这一使命的生动 践行。始终以守护百 ...
产品量价齐升 保龄宝上半年净利增长超三成
8月26日晚,代糖行业龙头企业保龄宝(002286)发布2025年半年度报告,报告期内实现营业收入13.99 亿元,同比增长18.02%;净利润9267.2万元,同比增长33.66%。 值得关注的是,今年1月16日,欧盟委员会公布了关于本次赤藓糖醇反倾销调查终裁公告,对国内赤藓 糖醇生产企业征收34.4%-233.3%不等的反倾销税。上述反倾销措施于欧盟终裁公告发布次日(即2025年1 月17日)起生效,实施期限为5年。其中保龄宝相关产品被征收34.4%的反倾销税,为本次反倾销加征税 率最低的企业。 保龄宝表示,公司抓住反倾销税率最低带来的市场机遇,赤藓糖醇产品在欧洲地区实现量价齐升,良好 的国际影响力和品牌力也带动了国内销售。 项目建设进展方面,保龄宝于2024年利用部分富裕产线进行改造,建立了DHA藻油生产线,初步计划 年产2000吨DHA藻油毛油。同年,该公司启动乳果糖项目的生产及上市许可注册工作。此外,保龄宝 还启动新建"年产2,500吨HMOs(母乳低聚糖)建设项目"。上述项目预计2025年下半年投产。 2025年3月,保龄宝了启动年产2万吨阿洛酮糖(二期)扩产项目,目前已完成备案正在建设中。预计2 ...
天然博士联合京东健康发布DHA品质标准 共筑好营养质量防线
Zhong Guo Fa Zhan Wang· 2025-08-20 02:45
政策与需求驱动DHA藻油标准升级,多方联合共筑品质防线 京东健康妇幼保健业务负责人张博在发布会的开场致辞中指出,伴随着生育友好型社会的构建,母 婴营养需求持续激增,消费者在选择婴童营养品时越来越看重"安全"与"品质"。在此背景下,京东健康 和天然博士希望用明确的标准,帮助消费者做出更明智的选择,联合制定了DHA藻油的质量标准。 在DHA藻油领域,天然博士当得上是行业领军品牌。天然博士已连续4年蝉联高端DHA藻油凝胶糖 果全国销量、销售额双第一[1]。其产品采用行业唯一授权life'sDHA™金标藻油[2]作为原料,更在专业 先进的透明工厂生产,生产过程透明化,让安全"看得见"。 佰腾药业市场总监胡寅表示,作为京东健康DHA标准的联合制定者,天然博士"科研为基、原料为 核、生产为盾"的实践路径与京东健康的核心理念高度契合。 8月18日,专业婴童营养品牌天然博士联合京东健康召开"京东好营养,藻油金标准"发布会,发布 了《京东好营养-DHA品质认证质量标准》,并汇聚了DHA产业链的关键代表共同探讨标准的落地。 据了解,京东健康和天然博士共同制定的《京东好营养-DHA品质认证质量标准》明确了好的DHA 产品的各项核心 ...
股市必读:保龄宝(002286)7月3日董秘有最新回复
Sou Hu Cai Jing· 2025-07-03 16:43
Core Viewpoint - The company Baolingbao (002286) is currently facing challenges in the market, with its stock price at 12.55 yuan, down 2.03%, and significant trading activity noted on July 3, 2025 [1] Group 1: Company Developments - The company clarified that its DHA algal oil production does not strictly fall under the definition of marine economy as outlined in the national marine economic development plan [1] - Baolingbao's product, Alotose, has not yet been approved for sale in the domestic market, and the approval timeline for its enzyme preparation remains uncertain [1] - The company has submitted an application for the domestic approval of its Alotose enzyme preparation, but it is still pending [1] Group 2: Market Activity - On July 3, 2025, the net outflow of main funds from Baolingbao was 102 million yuan, while speculative funds saw a net inflow of 26.07 million yuan, and retail investors contributed a net inflow of 75.65 million yuan [1]
保龄宝今年一季度业绩创历史新高 产品升级成效显著
Zheng Quan Ri Bao Wang· 2025-04-29 12:16
Core Viewpoint - Baolingbao achieved significant growth in Q1 2025, with a revenue of 685 million yuan, a year-on-year increase of 24.23%, and a net profit of 50.36 million yuan, up 117.35%, both reaching historical highs for the period [1] Group 1: Financial Performance - The company's comprehensive gross profit margin increased to 13.65%, up 3.67% from the same period last year [1] - The gross profit margin for the three core products (prebiotics, dietary fiber, and sugar-reducing sweeteners) reached 18.36% [1] Group 2: Product Demand and Market Strategy - There is a growing demand for sugar-reducing sweeteners, with the company's revenue from these products increasing by approximately 96% in Q1 [2] - The revenue growth for specific products includes erythritol (up 123%), allulose (up 82%), and crystalline fructose (up 80%) [2] Group 3: Project Development and Innovation - The production lines for DHA algae oil, lactulose, and HMOs have been completed and are in trial production [2] - The company has initiated the expansion project for allulose and is actively advancing the approval process for HMOs and allulose [2] - In Q1 2025, the company received three invention patent authorizations and participated in multiple industry standard formulations [2] Group 4: Market Outlook and Strategic Focus - The health food market is expected to enter a golden development period, with increasing consumer demand for functional ingredients like prebiotics and dietary fiber [2] - The company aims to leverage its technological advantages and market position to optimize product structure and innovate, adopting a "small, fine, and agile" model to meet differentiated demands [2] - Baolingbao plans to expand its domestic and international markets by utilizing its global layout and brand strength [2]